|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 5.180 USD | -1.89% |
|
-14.66% | +157.71% |
| 09-11 | HEALTH ROUNDS-Experimental eye drops ease night vision problems for drivers | RE |
| 09-10 | Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 439M | - | - | - | ||
| 1,027B | |||||
| 651B | - | ||||
| 467B | |||||
| 350B | |||||
| 268B |
- Stock Market
- Stocks
- IRD Stock
- Charts Opus Genetics, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
